Apeiron initiates clinical study to investigate prevention of radiation- induced skin damage in breast cancer patients

APEIRON Biologics AG (Apeiron) today announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Press release Presseaussendung

February 27, 2012
View the Post